These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 36318705)

  • 21. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
    J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
    Kwon DH; Chou J; Yip SM; Reimers MA; Zhang L; Wright F; Dhawan MS; Borno HT; Desai A; Aggarwal RR; Wyatt AW; Small EJ; Alva AS; Chi KN; Feng FY; Koshkin VS
    Cancer; 2021 Jun; 127(12):1965-1973. PubMed ID: 33690902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
    Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in
    Li Y; Lin S; Zhong L; Luo S; Huang X; Huang X; Dong L; Xu X; Weng X
    Pharmacogenomics; 2021 Aug; 22(13):809-819. PubMed ID: 34517749
    [No Abstract]   [Full Text] [Related]  

  • 25. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
    Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.
    Chen S; Zhong D; Yu C; Cai D; Wei Q; Yang M; Li T; Zhu Q; Ye L; Wei Y; Wu J
    Sci Rep; 2024 Aug; 14(1):19895. PubMed ID: 39191899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With
    Fallah J; Xu J; Weinstock C; Brave MH; Bloomquist E; Fiero MH; Schaefer T; Pathak A; Abukhdeir A; Bhatnagar V; Chiu HJ; Ricks T; John C; Hamed S; Lee C; Pierce WF; Kalavar S; Philip R; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman D
    J Clin Oncol; 2024 Feb; 42(5):605-613. PubMed ID: 38127780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
    Chi KN; Rathkopf D; Smith MR; Efstathiou E; Attard G; Olmos D; Lee JY; Small EJ; Pereira de Santana Gomes AJ; Roubaud G; Saad M; Zurawski B; Sakalo V; Mason GE; Francis P; Wang G; Wu D; Diorio B; Lopez-Gitlitz A; Sandhu S;
    J Clin Oncol; 2023 Jun; 41(18):3339-3351. PubMed ID: 36952634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
    Stopsack KH
    Eur Urol; 2021 Apr; 79(4):442-445. PubMed ID: 33012578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
    Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
    J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
    Carr TH; Adelman C; Barnicle A; Kozarewa I; Luke S; Lai Z; Hollis S; Dougherty B; Harrington EA; Kang J; Saad F; Sala N; Thiery-Vuillemin A; Clarke NW; Hodgson D; Barrett JC
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    Sokolova AO; Marshall CH; Lozano R; Gulati R; Ledet EM; De Sarkar N; Grivas P; Higano CS; Montgomery B; Nelson PS; Olmos D; Sokolov V; Schweizer MT; Yezefski TA; Yu EY; Paller CJ; Sartor O; Castro E; Antonarakis ES; Cheng HH
    Prostate; 2021 Dec; 81(16):1382-1389. PubMed ID: 34516663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer.
    Hommerding M; Hommerding O; Bernhardt M; Kreft T; Sanders C; Tischler V; Basitta P; Pelusi N; Wulf AL; Ohlmann CH; Ellinger J; Ritter M; Kristiansen G
    World J Urol; 2024 Aug; 42(1):491. PubMed ID: 39172235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-Gene Next-Generation Sequencing Panel for Analysis of
    Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
    Dong B; Yang B; Chen W; Du X; Fan L; Yao X; Xue W
    Med Oncol; 2022 May; 39(5):96. PubMed ID: 35599270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
    Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
    ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
    Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.